| Quarterly Financials | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 1,345 | 1,612 | 1,709 | 2,229 | 1,574 | 1,777 | 1,814 | 2,196 | 1,802 | 1,980 | 2,034 | 2,591 | 1,993 | 2,320 | 2,233 | 2,812 | 2,031 | 2,124 |
| Expenses | 1,197 | 1,381 | 1,314 | 1,733 | 1,465 | 1,554 | 1,629 | 1,812 | 1,617 | 1,646 | 1,723 | 2,053 | 1,747 | 1,900 | 1,867 | 2,193 | 1,827 | 1,885 |
| EBITDA | 148 | 231 | 395 | 495 | 109 | 223 | 185 | 384 | 185 | 334 | 312 | 538 | 246 | 420 | 367 | 619 | 204 | 239 |
| Operating Profit % | 9 % | 12 % | 15 % | 19 % | 1 % | 10 % | 5 % | 16 % | 8 % | 14 % | 12 % | 20 % | 10 % | 15 % | 15 % | 20 % | 6 % | 8 % |
| Depreciation | 136 | 138 | 147 | 165 | 162 | 166 | 164 | 184 | 174 | 185 | 186 | 196 | 185 | 192 | 197 | 243 | 197 | 203 |
| Interest | 42 | 49 | 50 | 57 | 62 | 83 | 95 | 104 | 119 | 110 | 106 | 114 | 107 | 108 | 103 | 104 | 86 | 82 |
| Profit Before Tax | -30 | 44 | 198 | 273 | -115 | -26 | -74 | 95 | -107 | 40 | 19 | 228 | -45 | 120 | 67 | 273 | -79 | -46 |
| Tax | -2 | 7 | 35 | 69 | -6 | 11 | 17 | 45 | -9 | 35 | 9 | 126 | 44 | 98 | 63 | 119 | 3 | 53 |
| Net Profit | -28 | 37 | 163 | 204 | -109 | -37 | -90 | 50 | -99 | 5 | 10 | 101 | -89 | 23 | 4 | 154 | -82 | -99 |
| EPS in ₹ | 0.00 | 0.31 | 1.38 | 1.72 | -0.92 | -0.31 | -0.76 | 0.42 | -0.83 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 | -0.75 |
Piramal Pharma
Piramal Pharma
199.33
-1.09
(-0.54%)
Company has added their latest Presentation1 day ago
Show All
Key Fundamentals
Market Cap
26,495.90 Cr
EPS
0.69
PE Ratio
-1,107.22
Dividend Yield
0.07 %
Industry
Healthcare 52 Week High
307.90
52 Week Low
181.73
PB Ratio
3.28
Debt to Equity
0.60
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from9 analysts
Actual
Company News
View All News
Piramal Pharma Expects Flat Revenue Growth and Moderating EBITDA Margins21 hours ago
Piramal Pharma anticipates flat revenue growth for the current year alongside moderating EBITDA margins. The company shared these expectations during a conference call update.
Piramal Pharma Limited announced quarterly results for the period ended September 30, 2025, with consolidated revenue from operations declining 21% year-over-year to ₹2,044 crores in Q2FY26. The company attributed the revenue decline primarily to inventory destocking by a customer in one large CDMO order for an on-patent commercial product. Half-year revenue fell 14% to ₹3,977 crores. EBITDA margins stood at 11% for the quarter and 10% for the half-year. The company's net debt reduced by ₹228 crores to ₹3,971 crores compared to FY25, maintaining a net debt to EBITDA ratio below 3x. The CDMO business was impacted by inconsistent recovery in US biopharma funding and uncertainties in global trade policies. However, the company noted a significant pickup in biopharma funding in September and October 2025. The Consumer Healthcare business delivered healthy mid-teen growth, while the Complex Hospital Generics business maintained its leadership position in the US Sevoflurane market with 45% value market share.
Piramal Pharma expects to capitalize on growing demand in the Contract Research, Development and Manufacturing Organization (CRDMO) sector. The company projects a compound annual growth rate of approximately 19% for its CRDMO sales over the FY2026-28 period, positioning itself to benefit from favorable market conditions in this segment.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,685.90 | #1 4,04,503.90 | 38.58 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 54.39 | |
6,883.50 | 1,82,735.30 | 79.27 | 9,712.00 | 18.67 | 2,191 | 26.74 | 74.24 | |
1,501.50 | 1,21,284.30 | 22.30 | 28,409.50 | 7.12 | 5,291 | 3.71 | 39.79 | |
3,553.40 | 1,20,263.20 | 60.08 | 11,539.40 | 6.99 | 1,911 | 19.91 | 46.89 | |
1,205.20 | 1,00,587.70 | #1 17.53 | 33,741.20 | 16.73 | 5,725 | -0.38 | 36.98 | |
2,309.10 | 95,310.10 | 49.83 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 28.96 | |
936.70 | 94,253.90 | 20.00 | 23,511.00 | 18.55 | 4,615 | 34.60 | 30.29 | |
1,955.50 | 89,318.30 | 24.00 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 50.08 | |
5,643.50 | 67,476.50 | 28.92 | 13,458.30 | 3.70 | 2,216 | 21.39 | 62.15 | |
1,140.60 | 66,246.20 | 19.54 | 32,345.60 | 9.43 | 3,484 | 3.81 | 59.80 |
Growth Rate
Revenue Growth
11.25 %
Net Income Growth
411.80 %
Cash Flow Change
-11.17 %
ROE
386.96 %
ROCE
22.30 %
EBITDA Margin (Avg.)
3.53 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 |
| Fixed Assets | 6,106 | 6,879 | 7,469 | 7,990 | 8,133 |
| Current Assets | 3,649 | 4,067 | 4,836 | 5,465 | 5,797 |
| Capital Work in Progress | 627 | 1,172 | 1,419 | 1,116 | 977 |
| Investments | 123 | 267 | 639 | 385 | 291 |
| Other Assets | 4,045 | 4,478 | 4,996 | 5,821 | 6,277 |
| Total Liabilities | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 |
| Current Liabilities | 2,490 | 3,033 | 3,843 | 4,369 | 3,766 |
| Non Current Liabilities | 2,805 | 3,067 | 3,906 | 3,031 | 3,786 |
| Total Equity | 5,605 | 6,697 | 6,774 | 7,911 | 8,126 |
| Reserve & Surplus | 4,610 | 5,511 | 5,580 | 6,588 | 6,801 |
| Share Capital | 995 | 1,186 | 1,193 | 1,323 | 1,324 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 110 | -177 | -32 | 166 | -37 |
| Investing Activities | -4,464 | -1,737 | -1,334 | -416 | -488 |
| Operating Activities | 598 | 766 | 484 | 1,005 | 892 |
| Financing Activities | 3,977 | 794 | 818 | -422 | -441 |
Share Holding
| % Holding | Sept 2022 | Oct 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 34.79 % | 0.00 % | 34.79 % | 34.79 % | 34.79 % | 35.02 % | 35.02 % | 35.02 % | 35.02 % | 34.95 % | 34.95 % | 34.95 % | 34.95 % | 34.86 % | 34.86 % |
| FIIs | 20.00 % | 0.00 % | 20.00 % | 20.00 % | 20.00 % | 18.04 % | 32.37 % | 32.51 % | 30.59 % | 31.42 % | 31.73 % | 31.68 % | 31.49 % | 30.86 % | 30.27 % |
| DIIs | 4.86 % | 0.00 % | 5.28 % | 4.99 % | 5.49 % | 7.83 % | 8.02 % | 9.68 % | 12.12 % | 12.95 % | 13.81 % | 14.10 % | 14.78 % | 14.26 % | 14.89 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.42 % | 0.00 % | 11.80 % | 13.94 % | 16.77 % | 16.81 % | 16.95 % | 15.57 % | 15.13 % | 13.94 % | 13.29 % | 13.29 % | 13.11 % | 14.07 % | 14.12 % |
| Others | 32.92 % | 100.00 % | 28.14 % | 26.29 % | 22.95 % | 22.30 % | 7.64 % | 7.22 % | 7.14 % | 6.74 % | 6.22 % | 5.98 % | 5.66 % | 5.95 % | 5.86 % |
| No of Share Holders | 1,79,957 | 1,79,948 | 2,29,960 | 2,41,359 | 2,77,270 | 2,95,773 | 2,97,225 | 2,92,312 | 2,97,996 | 3,06,398 | 3,59,751 | 4,18,442 | 4,32,843 | 4,58,430 | 4,62,511 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.00 | 0.11 | 0.14 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.00 | 0.05 | 0.07 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 02 Aug 2023 |  Rights | 5:46 | 02 Aug 2023 | 101.95 | 103.86 |
| 12 Jul 2024 |  Dividend | ₹ 0.11 /share | 12 Jul 2024 | 148.05 | 151.60 |
| 26 Jul 2024 |  Annual General Meeting | NA | 26 Jul 2024 | 157.10 | 166.30 |
| 23 Oct 2024 |  Quarterly Result Announcement | NA | 23 Oct 2024 | 221.30 | 215.15 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 221.25 | 224.00 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 214.95 | 214.90 |
| 16 Jul 2025 | Dividend | ₹ 0.14 /share | 16 Jul 2025 | 214.90 | 216.22 |
| 28 Jul 2025 | Quarterly Result Announcement | NA | 28 Jul 2025 | 216.88 | 202.23 |
| 30 Jul 2025 | Annual General Meeting | NA | 30 Jul 2025 | 199.95 | 205.61 |
| 05 Nov 2025 | Quarterly Result Announcement | NA | 05 Nov 2025 | 203.60 | 200.42 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19 hours ago
19 hours agoAnnouncement under Regulation 30 (LODR)-Investor Presentation1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
1 day agoResults - Financial Results For Quarter Ended September 30 20251 day ago
1 day agoBoard Meeting Outcome for Outcome Of Board Meeting Dated November 5 20251 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 24, 2025
Oct 24, 2025Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September 2025.Oct 24, 2025
Oct 24, 2025Announcement under Regulation 30 (LODR)-Credit RatingOct 16, 2025
Oct 16, 2025General - UpdateSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Sep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Sustainability Report - FY2024-25Aug 25, 2025
Aug 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 20, 2025
Aug 20, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Jul 31, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 30, 2025
Jul 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 29, 2025
Jul 29, 2025Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2025Jul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 28Th July 2025Jul 28, 2025
Jul 28, 2025Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of Stock OptionsJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-RestructuringJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Credit RatingJul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Jul 18, 2025Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Jul 18, 2025
Jul 18, 2025Announcement Under Regulation 30 (LODR) - ESG RatingJul 10, 2025
Jul 10, 2025Company Update On LitigationJul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Jul 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 02, 2025
Jul 02, 2025Notice Of The 5Th Annual General Meeting (AGM) And Annual Report For The Financial Year 2024-25Jul 02, 2025
Jul 02, 2025Reg. 34 (1) Annual Report.Jul 02, 2025
Jul 02, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2025
Jun 26, 2025Corporate Action-Board to consider DividendJun 13, 2025
Jun 13, 2025Intimation Of Record Date For Payment Of Final DividendJun 13, 2025
Jun 13, 2025Intimation Of 5Th Annual General Meeting To Be Held On Wednesday July 30 2025Jun 13, 2025
Jun 13, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)Jun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 02, 2025
Jun 02, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Mutual Fund Holdings
HDFC Flexi Cap Direct Plan-Growth 
Bandhan Small Cap Fund Direct-Growth 
Canara Robeco Small Cap Fund Direct - Growth 
Franklin India Opportunities Direct Fund-Growth 
Aditya Birla Sun Life Small Cap Fund Direct-Growth 
Kotak Manufacture in India Fund Direct - Growth 
ICICI Prudential Multicap Fund Direct Plan-Growth 
LIC MF Manufacturing Fund Direct-Growth 
Tata Flexi Cap Fund Direct - Growth 
Invesco India Manufacturing Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 52.36
ATR(14)
Less Volatile 4.79
STOCH(9,6)
Neutral 61.91
STOCH RSI(14)
Neutral 56.20
MACD(12,26)
Bullish 0.28
ADX(14)
Weak Trend 12.58
UO(9)
Bearish 43.38
ROC(12)
Uptrend And Accelerating 3.22
WillR(14)
Neutral -39.56
About Piramal Pharma
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
Chairperson NameNandini Piramal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
